The Food and Drug Administration (FDA) has cleared Cohealyx – a collagen-based dermal matrix designed for tissue integration and revascularation.  

According to AVITA Medical, the company which co-developed the product alongside Regenity Biosciences, Cohealyx consists of an advanced bovine collagen-based design that facilitates cellular migration and blood vessel formation. The company said, “Preclinical studies in porcine models demonstrated that Cohealyx generated robust tissue capable of consistently supporting a split-thickness skin graft in a two-stage procedure earlier than leading dermal matrices in the study.”  

The product’s capabilities will next be evaluated in real-world settings, focusing on clinical efficacy and cost savings in treating full thickness wounds and burns.